ES2139559T3 - Nueva forma cristalina de omeprazol. - Google Patents

Nueva forma cristalina de omeprazol.

Info

Publication number
ES2139559T3
ES2139559T3 ES98957255T ES98957255T ES2139559T3 ES 2139559 T3 ES2139559 T3 ES 2139559T3 ES 98957255 T ES98957255 T ES 98957255T ES 98957255 T ES98957255 T ES 98957255T ES 2139559 T3 ES2139559 T3 ES 2139559T3
Authority
ES
Spain
Prior art keywords
omeprazol
crystal form
new crystal
new
omeprazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98957255T
Other languages
English (en)
Other versions
ES2139559T1 (es
Inventor
Karin Lovqvist
David Noreland
Gunnel Sunden
Ingvar Ymen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27543202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2139559(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of ES2139559T1 publication Critical patent/ES2139559T1/es
Application granted granted Critical
Publication of ES2139559T3 publication Critical patent/ES2139559T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Omeprazol en la forma A, caracterizado por ser termodinámicamente estable a temperatura ambiente.
ES98957255T 1998-11-10 1998-11-10 Nueva forma cristalina de omeprazol. Expired - Lifetime ES2139559T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE29823393U DE29823393U1 (de) 1998-11-10 1998-11-10 Neue kristalline Form von Omeprazol
BR9816067-2A BR9816067A (pt) 1998-11-10 1998-11-10 Forma a de omeprazol, omeprazol, processo para a preparação da forma a de omeprazol, formulação farmacêutica, uso de omeprazol, e, método de tratamento de distúrbios gastrointestinais.
CA002363810A CA2363810A1 (en) 1998-11-10 1998-11-10 New form of omeprazole
PCT/SE1998/002028 WO1999008500A2 (en) 1998-11-10 1998-11-10 New crystalline form of omeprazole
EP98957255A EP0969819B1 (en) 1998-11-10 1998-11-10 New crystalline form of omeprazole
US10/076,225 US20020156284A1 (en) 1998-11-10 2002-02-13 Crystalline form of omeprazole

Publications (2)

Publication Number Publication Date
ES2139559T1 ES2139559T1 (es) 2000-02-16
ES2139559T3 true ES2139559T3 (es) 2003-10-01

Family

ID=27543202

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98957255T Expired - Lifetime ES2139559T3 (es) 1998-11-10 1998-11-10 Nueva forma cristalina de omeprazol.

Country Status (33)

Country Link
US (3) US6150380A (es)
EP (2) EP1221314A1 (es)
JP (1) JP3457945B2 (es)
CN (1) CN1347413A (es)
AT (1) ATE233755T1 (es)
AU (1) AU756434B2 (es)
BR (1) BR9816067A (es)
CA (2) CA2284470C (es)
CZ (1) CZ301635B6 (es)
DE (3) DE969819T1 (es)
DK (2) DK0969819T3 (es)
DZ (1) DZ2669A1 (es)
EE (1) EE04279B1 (es)
ES (1) ES2139559T3 (es)
FI (1) FI3873U1 (es)
GR (1) GR990300034T1 (es)
HR (1) HRP20010281B1 (es)
HU (1) HUP0104379A3 (es)
IL (1) IL142703A0 (es)
IS (1) IS2025B (es)
MA (1) MA26574A1 (es)
NO (1) NO320014B1 (es)
NZ (1) NZ511377A (es)
PL (1) PL190870B1 (es)
PT (1) PT969819E (es)
RU (1) RU2207339C2 (es)
SI (1) SI0969819T1 (es)
SK (1) SK286562B6 (es)
TR (1) TR200101282T2 (es)
TW (1) TW533203B (es)
UA (1) UA72748C2 (es)
WO (1) WO1999008500A2 (es)
ZA (1) ZA9811174B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SI20019A (sl) 1998-07-13 2000-02-29 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola
IL142703A (en) * 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
US6262085B1 (en) * 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6262086B1 (en) * 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6750064B2 (en) * 2000-12-28 2004-06-15 S.S.C.I. Inc. Methods of screening for possible solid forms
SI20875A (sl) * 2001-04-25 2002-10-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristalna oblika omeprazola
US7855082B1 (en) 2001-10-31 2010-12-21 Astrazeneca Ab Raman spectroscopic method for determining the ratio of 5-methoxy and 6-methoxy isomers of omeprazole
JP2006516574A (ja) 2003-02-05 2006-07-06 テバ ファーマシューティカル インダストリーズ リミティド ランソプラゾール安定化方法
US20040235904A1 (en) * 2003-03-12 2004-11-25 Nina Finkelstein Crystalline and amorphous solids of pantoprazole and processes for their preparation
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005037424A1 (en) * 2003-10-06 2005-04-28 Solvias Ag Process for the parallel detection of crystalline forms of molecular solids
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US20060160783A1 (en) * 2004-12-30 2006-07-20 Transform Pharmaceuticals, Inc. Novel omeprazole forms and related methods
JP2008545768A (ja) * 2005-06-08 2008-12-18 レツク・フアーマシユーテイカルズ・デー・デー オメプラゾールナトリウムの結晶性溶媒和物
EP1904064A4 (en) * 2005-07-07 2009-12-02 Reddys Lab Ltd Dr OMEPRAZOLE OF FORM B
CA2624179A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
GB2444593B (en) 2006-10-05 2010-06-09 Santarus Inc Novel formulations for immediate release of proton pump inhibitors and methods of using these formulations
MX2009004475A (es) 2006-10-27 2009-08-12 Univ Missouri Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
WO2008092939A2 (en) 2007-01-31 2008-08-07 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic separation
US20090010388A1 (en) * 2007-06-06 2009-01-08 Stahly Barbara C Microplate and methods of using the same
US8018588B2 (en) * 2007-06-06 2011-09-13 Aptuit, Inc. Sample holder and sample preparation device
US20090104236A1 (en) * 2007-10-18 2009-04-23 Pharmaceutics International, Inc. Pharmaceutical solid hybrids
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
US20090280175A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Proton Pump Inhibitor Tablets
WO2010134099A1 (en) 2009-05-21 2010-11-25 Cadila Healthcare Limited One pot process for preparing omeprazole and related compounds
BR112012010525A2 (pt) * 2009-11-03 2015-09-29 Glaxo Group Ltd novos processos
GB201001075D0 (en) 2010-01-22 2010-03-10 Cyclacel Ltd Crystalline forms
RU2501549C1 (ru) 2012-08-30 2013-12-20 Авва Девелопмент Лтд Фармацевтическая композиция для лечения гастроэзофагеальной рефлюксной болезни
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
RU2726320C1 (ru) * 2020-02-09 2020-07-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КемГМУ) Способ определения примесных компонентов омепразола
JP2025532389A (ja) 2022-10-04 2025-09-29 ザビリュク，アルセニー 大動脈弁の石灰化の抑制
CN119320380B (zh) * 2024-10-14 2025-11-25 山东益康药业股份有限公司 奥美拉唑与2,6-二羟基苯甲酸的共晶物及其用途
CN119320381B (zh) * 2024-10-14 2025-12-12 山东益康药业股份有限公司 奥美拉唑与3,5-二硝基苯甲酸的共晶物及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
SE9002043D0 (sv) * 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
CA2044706C (en) 1990-06-15 2003-02-25 Michael Midler Jr. Crystallization method to improve crystal structure and size
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
WO1995018612A1 (en) * 1994-01-05 1995-07-13 Aktiebolaget Astra A method for treatment of psoriasis, by omeprazole or related compounds
US5856493A (en) * 1995-02-06 1999-01-05 Smithkline Beecham Corporation Process for making novel form of paroxeting hydrochloride anhydrate
SE521100C2 (sv) * 1995-12-15 2003-09-30 Astra Ab Förfarande för framställning av en bensimidazolförening
TW385306B (en) 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE9704183D0 (sv) 1997-11-14 1997-11-14 Astra Ab New process
US6166213A (en) 1998-08-11 2000-12-26 Merck & Co., Inc. Omeprazole process and compositions thereof

Also Published As

Publication number Publication date
DK199900074U1 (da) 2000-02-10
WO1999008500A3 (en) 1999-07-29
EP0969819B1 (en) 2003-03-05
SK5452001A3 (en) 2001-11-06
JP3457945B2 (ja) 2003-10-20
ES2139559T1 (es) 2000-02-16
IS5935A (is) 2001-05-07
CA2363810A1 (en) 1999-02-25
HUP0104379A2 (hu) 2002-04-29
NO320014B1 (no) 2005-10-10
WO1999008500A2 (en) 1999-02-25
PL190870B1 (pl) 2006-02-28
FIU980578U0 (fi) 1998-12-21
BR9816067A (pt) 2001-08-07
DE69811868D1 (de) 2003-04-10
HUP0104379A3 (en) 2003-01-28
EP0969819A2 (en) 2000-01-12
HRP20010281B1 (en) 2004-04-30
DZ2669A1 (fr) 2003-03-22
GR990300034T1 (en) 2000-07-31
PL348247A1 (en) 2002-05-20
NZ511377A (en) 2003-04-29
CZ20011611A3 (cs) 2002-01-16
CA2284470A1 (en) 1999-02-25
EE200100248A (et) 2002-10-15
NO20012286D0 (no) 2001-05-09
TR200101282T2 (tr) 2001-11-21
US6384059B1 (en) 2002-05-07
DE69811868T2 (de) 2004-03-04
IL142703A0 (en) 2002-03-10
IS2025B (is) 2005-08-15
SI0969819T1 (en) 2003-06-30
EE04279B1 (et) 2004-04-15
US6150380A (en) 2000-11-21
CZ301635B6 (cs) 2010-05-12
FI3873U1 (fi) 1999-03-22
US20020156284A1 (en) 2002-10-24
EP1221314A1 (en) 2002-07-10
MA26574A1 (fr) 2004-12-20
AU1355199A (en) 1999-03-08
CN1347413A (zh) 2002-05-01
UA72748C2 (en) 2005-04-15
DK0969819T3 (da) 2003-05-19
ATE233755T1 (de) 2003-03-15
TW533203B (en) 2003-05-21
DE29823393U1 (de) 1999-05-27
PT969819E (pt) 2003-06-30
NO20012286L (no) 2001-07-03
HRP20010281A2 (en) 2002-06-30
SK286562B6 (sk) 2009-01-07
AU756434B2 (en) 2003-01-16
ZA9811174B (en) 2000-06-07
HK1024242A1 (en) 2000-10-05
RU2207339C2 (ru) 2003-06-27
CA2284470C (en) 2002-02-26
JP2001522780A (ja) 2001-11-20
DE969819T1 (de) 2000-04-06

Similar Documents

Publication Publication Date Title
ES2139559T3 (es) Nueva forma cristalina de omeprazol.
CU23053A3 (es) 1,2,3,4-tetrahidroquinlinas 2-sustituidas 4-amino sustituidas
NO20011350D0 (no) 4-Karboksyaminosubstituerte 1,2,3,4-tetrahydrokinoliner som CETP inhibitorer
DK1114033T3 (da) 4-Carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoliner som CETP-inhibitorer
IS5875A (is) Ásetnar fenýlafleiður, framleiðsla þeirra og notkun
DE60003281D1 (de) Thermisches Übertragungsverfahren.
ATE435861T1 (de) 12,13-cyclopropan-epothilonderivate
EP1107735A4 (en) FORMULATION OF OMEPRAZOLE
NO20022558D0 (no) 4-karboksyamino-2-etyl-1,2,3,4-tetrahydrokinolinkrystall som CETP inhibitor
NO20010898L (no) Termoelement for bruk i gassifiseringsprosess
AU2003275716A1 (en) 3-benzoyl-2,4,5-substituted pyridine derivatives or salts thereof and bactericides containing the same
PT1191025E (pt) Cristais de lansoprazol
DE69933108D1 (de) Synchrone bitstromverschlüsselung
IL144349A0 (en) Non-nucleoside reverse transcriptase inhibitors
DE50107988D1 (de) Substituierte 1,2,3,4-tetrahydrochinolin-2-carbonsäurederivate
NO20003825L (no) 1,3,4 - oxadiazolonderivater
DE69928050D1 (de) Taktregenerator
PT1248618E (pt) Formas polimorficas, amorfas e hidratadas de 5-cloro-3-(4-metanossulfonilfenil)-6'-metil-[2,3']bipiridinilo
ATE322492T1 (de) Nicht-nukleosid reverse transkriptase inhibitoren
ZA200400652B (en) 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-((1,1-dioxo-1lambda6-thiomorpholin-4-yl)-4-(2-methyl or 4-fluoro-2-methyl substituted)phenyl-pyridin-3-yl]-N-methyl-isobutyramide.
ITBO980708A0 (it) Dispositivo formatore di gruppi di sigarette .
ATE432075T1 (de) Orale zusammensetzungen mit 8-chloro-6,11-dihydro-11-(4-piperidylene)-5h-be zoä5,6ü-cyclo-heptaä1,2-büpyridin
IT1311394B1 (it) Unita' di alimentazione di sigari.
FI980704A0 (fi) Foerfarande foer att saenda en synkroniserad kanal i en radiosaendare
EE200200615A (et) 1. tüüpi naatrium-vesinikvahetaja inhibiitor (NHE-1)